Efficacy, safety and policy implications of anti-amyloid monoclonal antibodies for Alzheimer's disease: protocol for a living systematic review and meta-analysis.
- DOI
- 10.1192/bjo.2026.12044
- Published
- 2026 Jul 9
- Container
- BJPsych open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1192/bjo.2026.12044,
title = {Efficacy, safety and policy implications of anti-amyloid monoclonal antibodies for Alzheimer's disease: protocol for a living systematic review and meta-analysis.},
author = {Kim S and Oda H and Oyama R and Makishi R and Bade S and Bade S and Ally I and Iijima Y and Gibo Y and Minami K and Fukuzawa F and Sanji S and Inamine K and Kishi H and Huh S and Tanifuji T and Nagahiro M and Watanabe N},
year = {2026},
journal = {BJPsych open},
doi = {10.1192/bjo.2026.12044},
url = {https://doi.org/10.1192/bjo.2026.12044}
}RIS
TY - JOUR TI - Efficacy, safety and policy implications of anti-amyloid monoclonal antibodies for Alzheimer's disease: protocol for a living systematic review and meta-analysis. AU - Kim S AU - Oda H AU - Oyama R AU - Makishi R AU - Bade S AU - Bade S AU - Ally I AU - Iijima Y AU - Gibo Y AU - Minami K AU - Fukuzawa F AU - Sanji S AU - Inamine K AU - Kishi H AU - Huh S AU - Tanifuji T AU - Nagahiro M AU - Watanabe N PY - 2026 JO - BJPsych open DO - 10.1192/bjo.2026.12044 UR - https://doi.org/10.1192/bjo.2026.12044 ER -
APA
S, K., H, O., R, O., R, M., S, B., S, B., I, A., Y, I., Y, G., K, M., F, F., S, S., K, I., H, K., S, H., T, T., M, N., & N, W. (2026). Efficacy, safety and policy implications of anti-amyloid monoclonal antibodies for Alzheimer's disease: protocol for a living systematic review and meta-analysis.. BJPsych open. https://doi.org/10.1192/bjo.2026.12044
Source records
- pubmed · retrieved 2026-09-25T04:08:12.904Z